Handelsavisen
prelaunch
Companies ›Healthcare ›183490.KQ
18
183490.KQ — KOSDAQ Pharmaceuticals

183490.Kq

$990,00
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-26,7 %
ROE
-13,2 %
Net margin
-26,8 %
Debt / equity
0,04
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

The company operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products.

Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
-13,2 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 183490.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 183490.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a low debt-to-equity ratio of 0.04, indicating a conservative leverage position relative to its equity base. Its liquidity position is strong, with a current ratio of 14.06, suggesting ample short-term assets to cover liabilities. However, the company's operating cash flow is negative at -11,012,139,980 KRW, and its free cash flow is also negative at -15,739,967,710 KRW, indicating a cash outflow from operations.

    Profitability metrics show a significant challenge, with a return on equity of -13.18% and a return on assets of -12.2%, both well below the industry norms for pharmaceutical companies. The company's operating income is negative at -18,079,359,770 KRW, and its net income is also negative at -18,131,506,690 KRW, reflecting a substantial loss for the period.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification may increase its exposure to market-specific risks, particularly in its primary operating region.

    The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. However, the negative operating and net income figures suggest a need for strategic adjustments to improve profitability and cash flow generation.

    Risk factors include the company's negative operating and free cash flows, which could impact its ability to fund operations and invest in growth initiatives. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's capital structure remains stable, with a low debt-to-equity ratio and a strong current ratio.

    Recent events, as disclosed in the latest financial filings, include a significant operating loss and a negative free cash flow, which may signal underlying operational challenges. No specific recent events or filings beyond the financial results have been disclosed in the available data.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 14.06, but it is experiencing negative operating and free cash flows.
    • The company's profitability is significantly below industry norms, with a return on equity of -13.18% and a return on assets of -12.2%.
    • The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
    • The company's capital structure is conservative, with a low debt-to-equity ratio of 0.04.
    • The company's risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected.
    • The company's growth trajectory is uncertain, with no specific revenue growth projections provided.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $990,00
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $137.54B
    Net cashⓘ
    $3.01B
    Current ratioⓘ
    14.1
    Debt / equityⓘ
    0.0
    ROAⓘ
    -12.2%
    ROEⓘ
    -13.2%
    Cash conversionⓘ
    61.0%
    CapEx / revenueⓘ
    -1.1%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-26,7 %Bottom quartile
    Net Margin-26,8 %Bottom quartile
    ROE-13,2 %Bottom quartile
    Capex / Rev-1,1 %Above P75
    D/E0,04Above median
    Cash Conv0,61Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 183490.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    183490.KQCanonical
    KOSDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage